Stock INDSWFTLAB IND-SWIFT LABORATORIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Ind-Swift Laboratories Limited Bombay S.E.

Equities

INDSWFTLAB

INE915B01019

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:00:50 2024-04-26 am EDT 		5-day change 1st Jan Change
124.8 INR +0.29% Intraday chart for Ind-Swift Laboratories Limited +5.35% +20.05%
Apr. 19 Ind-Swift Laboratories to Incorporate Wholly-Owned Arm in Dubai MT
Apr. 19 Ind-Swift Laboratories Limited Announces Incorporation of Wholly Owned Subsidiary CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 2,572 1,869 1,202 4,251 3,938 3,262
Enterprise Value (EV) 1 13,308 12,724 11,410 14,189 13,254 11,701
P/E ratio 11.7 x 6.17 x -4.75 x -135 x -183 x 6.85 x
Yield - - - - - -
Capitalization / Revenue 0.33 x 0.24 x 0.15 x 0.47 x 0.37 x 0.27 x
EV / Revenue 1.71 x 1.63 x 1.43 x 1.56 x 1.26 x 0.96 x
EV / EBITDA 11.7 x 11.8 x 8.88 x 8.54 x 5.96 x 4.9 x
EV / FCF 14.9 x -14.7 x 46.6 x 58 x 49.3 x 26.6 x
FCF Yield 6.72% -6.81% 2.15% 1.72% 2.03% 3.76%
Price to Book 0.46 x 0.31 x 0.19 x 0.7 x 0.66 x 0.48 x
Nbr of stocks (in thousands) 45,277 47,569 59,087 59,087 59,087 59,087
Reference price 2 56.80 39.30 20.35 71.95 66.65 55.20
Announcement Date 9/8/18 9/7/19 9/7/20 9/7/21 9/7/22 9/5/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 7,769 7,785 7,993 9,068 10,521 12,159
EBITDA 1 1,133 1,080 1,285 1,661 2,224 2,389
EBIT 1 620.9 540.5 739.6 1,110 924.1 1,815
Operating Margin 7.99% 6.94% 9.25% 12.24% 8.78% 14.93%
Earnings before Tax (EBT) 1 359.3 591.7 -197.7 180.1 125.3 862.9
Net income 1 219.2 384.4 -211.9 -31.47 -21.49 476
Net margin 2.82% 4.94% -2.65% -0.35% -0.2% 3.91%
EPS 2 4.860 6.369 -4.284 -0.5326 -0.3637 8.055
Free Cash Flow 1 894.8 -866.6 244.8 244.5 268.9 439.6
FCF margin 11.52% -11.13% 3.06% 2.7% 2.56% 3.62%
FCF Conversion (EBITDA) 78.99% - 19.05% 14.72% 12.09% 18.41%
FCF Conversion (Net income) 408.22% - - - - 92.37%
Dividend per Share - - - - - -
Announcement Date 9/8/18 9/7/19 9/7/20 9/7/21 9/7/22 9/5/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 10,736 10,855 10,207 9,938 9,315 8,439
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 9.478 x 10.05 x 7.944 x 5.983 x 4.189 x 3.533 x
Free Cash Flow 1 895 -867 245 245 269 440
ROE (net income / shareholders' equity) 4.04% 6.64% -3.45% -0.51% -0.36% 7.42%
ROA (Net income/ Total Assets) 1.87% 1.72% 2.44% 3.76% 3.19% 6.26%
Assets 1 11,751 22,404 -8,695 -837 -673.3 7,604
Book Value Per Share 2 122.0 127.0 108.0 102.0 102.0 115.0
Cash Flow per Share 2 2.090 6.300 1.790 1.960 3.630 3.080
Capex 1 205 153 107 39.1 184 128
Capex / Sales 2.63% 1.96% 1.34% 0.43% 1.75% 1.05%
Announcement Date 9/8/18 9/7/19 9/7/20 9/7/21 9/7/22 9/5/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Generic Pharmaceuticals

1st Jan change Capi.
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+19.62% 43.34B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+20.44% 21.96B
SANDOZ GROUP AG Stock Sandoz Group AG
+10.86% 14.09B
CIPLA LIMITED Stock Cipla Limited
+13.07% 13.64B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+37.46% 11.43B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.59% 6.86B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+8.46% 5.22B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. INDSWFTLAB Stock
  4. INDSWFTLAB Stock
  5. Financials Ind-Swift Laboratories Limited